DIGITALLY OR VISUALLY READ?

FOR UNAMBIGUOUS RESULTS YOU CAN TRUST

THE CHOICE IS CLEAR.

All rapid antigen COVID-19 testing looks about the same until it's time to interpret the results. That's when the difference between visually read tests and the digitally read **BD Veritor™ System** for Rapid Detection of SARS-CoV-2* test becomes very clear.



Visual read

Digital read

Interpret results

Is there a line?

How faint is it?

Do I test it again?

Clear results with the **BD Veritor™ Plus System**

CoV: +

Positive

or

CoV: –

Negative

BD

The clear advantage

The **BD Veritor™ Plus System** is an easy-to-use, one-button device that offers reliable results through a digitally read test assay that leaves little room for misinterpretation. The instrument analyzes and corrects for nonspecific binding and detects positives not recognized by the unaided eye to provide an objective result that you can count on.

Digitally read and displayed results
No interpretation required

Connectivity
Offers traceability, recording and reportability of results

Advanced particle technology
Improved test performance compared to visually read tests

Versatility
The BD Veritor™ Plus System offers a broad menu (Flu A + B, Group A Strep and RSV) of digitally read assays for respiratory infections

Positive control line
Provides confidence that the test was successful

Reliability
Reliable results as per the labeled instructions for use

To find out more about how the digitally read **BD Veritor™ Plus System** test assays can increase the confidence in your results, please visit **BDVeritor.com**

*This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

References:

1. BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2. Package insert. Becton, Dickinson and Company.

BDVeritor.com